Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last hours
Enjoy this offer
* See conditions under "Our services"

Valuation: Ocugen, Inc.

Market Cap 416M 359M 330M 311M 584M 39.3B 589M 3.91B 1.52B 19.29B 1.56B 1.53B 66.72B P/E 2026 *
-5.45x
P/E 2027 * -5.08x
Enterprise Value 354M 305M 281M 264M 496M 33.4B 501M 3.33B 1.29B 16.39B 1.33B 1.3B 56.7B EV / Sales 2026 *
86.8x
EV / Sales 2027 * 37.8x
Free-Float
98.28%
Yield 2026 *
-
Yield 2027 * -
1 day+6.91%
1 week+3.36%
Current month-10.87%
1 month-11.51%
3 months-49.80%
6 months-12.77%
Current year-8.89%
1 week 1.16
Extreme 1.16
1.28
1 month 1.16
Extreme 1.16
1.43
Current year 1.16
Extreme 1.16
2.72
1 year 0.9
Extreme 0.9029
2.72
3 years 0.34
Extreme 0.345
2.72
5 years 0.34
Extreme 0.345
17.65
10 years 0.17
Extreme 0.17
18.77
Manager TitleAgeSince
Chief Executive Officer 62 2019-09-26
Director of Finance/CFO - 2026-02-08
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Chairman 62 2019-09-26
Director/Board Member 59 2013-08-31
Director/Board Member 59 2019-08-31
Date Insider Type Main position Quantity % Market Cap.
06-10Free

Director

170,100 0.0502%
06-10Free

Director

170,100 0.0502%
06-10Free

Director

170,100 0.0502%
Change 5-day change 1-year change 3-year change Capi.($)
+5.28%+3.36%+12.84%+139.49% 416M
-0.89%-0.91%-12.88%-11.20% 43.44B
+2.92%+9.42%+303.09%+540.82% 33.54B
-1.09%-6.31%+10.75%-20.99% 28.48B
+3.75%-0.35%+3.38%+31.20% 29.2B
+0.06%+4.36%+13.31%+21.11% 25.34B
+1.61%+10.18% - - 14.36B
+0.79%-1.86%+53.43%+106.06% 13.05B
-0.77%-3.45%+2.68%+3.53% 12.67B
+1.14%+1.35%+105.56%+81.16% 12.28B
Average +1.42%+1.53%+54.68%+99.02% 21.28B
Weighted average by Cap. +0.80%+1.36%+62.40%+105.76%

Financials

2026 *2027 *
Net sales 4.08M 3.52M 3.23M 3.04M 5.72M 385M 5.77M 38.33M 14.92M 189M 15.3M 14.98M 653M 11.02M 9.51M 8.74M 8.23M 15.46M 1.04B 15.59M 104M 40.32M 510M 41.36M 40.47M 1.77B
Net income -76.84M -66.29M -60.95M -57.37M -108M -7.25B -109M -722M -281M -3.56B -288M -282M -12.31B -85.3M -73.59M -67.65M -63.68M -120M -8.05B -121M -802M -312M -3.95B -320M -313M -13.67B
Net Debt -62.5M -53.92M -49.57M -46.66M -87.68M -5.9B -88.41M -587M -229M -2.89B -235M -230M -10.01B -
Logo Ocugen, Inc.
Ocugen, Inc. is a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines that improve health and offer hope for patients across the globe. Its technology pipeline includes Novel Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, and Inhaled Mucosal Vaccine Platform. It is developing its modifier gene therapy platform, inclusive of OCU400, OCU410, and OCU410ST, for the treatment of multiple inherited retinal diseases, including retinitis pigmentosa, Stargardt disease and multifactorial diseases, such as dry age-related macular degeneration (dAMD) and geographic atrophy. It is developing a next-generation, inhalation-based mucosal vaccine platform based on a novel ChAd vector, which includes OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine, and OCU520, a combination quadrivalent seasonal flu.
Employees
116
Date Price Change Volume
26-06-17 1.230 $ +4.24% 6,326,911
26-06-16 1.180 $ -3.28% 7,714,206
26-06-15 1.220 $ +0.83% 6,340,386
26-06-12 1.210 $ -0.82% 3,743,289
26-06-11 1.220 $ +2.52% 4,858,313
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
1.230USD
Average target price
11.43USD
Spread / Average Target
+829.15%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. OCGN Stock
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!